Disitamab Vedotin — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	46	27	9	58	—	—	Sep 26, 2018
Malignant Breast Neoplasm	Phase3	Phase 3	9	6	1	10	—	—	Mar 1, 2023
Malignant Gastric Neoplasm	Phase3	Phase 3	8	5	2	10	—	—	Jan 1, 2023
Malignant Bladder Neoplasm	Phase3	Phase 3	4	2	1	4	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDK12 Amplification + ERBB2 AmplificationERBB2 CDK121

Clinical trials

Trials with this intervention (60)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 60 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07498907	Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma(LUXUS41)	recruiting	Phase 3	192	Peking University First HospitalOTHER	1	Sep 28, 2026	clinicaltrials
NCT07315750	A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.